Cracking the CAR T Code for Solid Tumors
AffyImmune is a clinical stage biotech company bringing the benefits of CAR T to the majority of cancer patients
Our Science
AffyImmune is developing the next generation of cellular therapies to enhance the ability of a patient’s own immune system to detect and eliminate tumor cells where ICAM-1 is overexpressed.
Affinity Tuning
With its groundbreaking approach, AffyImmune fine tunes the affinity of CAR T cells to selectively kill tumor cells while sparing healthy cells.
Noninvasive Monitoring
AffyImmune engineers CAR T cells to be monitorable – non-invasively – in patients during treatment.
Focus on ICAM-1
ICAM-1 is a master regulator of many essential cellular functions at the onset and resolution of pathological conditions. AffyImmune is focused on cancers where ICAM-1 overexpression plays a key role.
Clinical Indications
Although most thyroid cancers are curable, prognosis is very poor for anaplastic and refractory thyroid cancers (ARTC). AffyImmune's lead candidate, AIC100, is an ICAM-1-directed CAR T therapy being developed for patients with ARTC.
